Harvest One Cannabis Inc. (TSX-V:HVST) announced that Satipharm, its European subsidiary,  has improved its international business prospects with several developments.

 Germany has granted it a Free Sales Certificate, which reduces constraints on Saitpharm’s exports. The certificate establishes Satipharm’s CBD capsules as a food supplement instead of a novel food. The company expects this to increase its successful exporting to other European countries.

 Satipharm focuses on large European markets including Germany, Denmark, UK, Ireland, Netherlands, Spain, and Austria. Its sales are increasing month over month. The company expects sales to hit C$180,000 in the first quarter of 2018.

Satipharm’s CBD capsules were recently approved by Australian authorities, which approve it based on its quality. These capsules will now become available in Australia.

United Greeneries Operations, another Harvest One subsidiary, has applied to become a licensed dealer in Canada of Satipharm’s CBD capsules.  

Satipharm’s manufacturing partners in Switzerland have been approved to produce products containing THC. These products will be available in Canada and Australia in early 2018.

Source: Harvest One

Leave a Reply